HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

People In Brief

This article was originally published in The Tan Sheet

Executive Summary

Rep. Burton retires; OTC veteran Arnett leads Matrixx; Alkalife hires new leadership, including founder’s son; Clark joins Captek Softgel; more People In Brief.

You may also be interested in...



Burton Bill Would Move Up New Dietary Ingredient Grandfather Date To 2007

Rep. Burton offers legislation to move up from 1994 to 2007 the date delineating old from new dietary ingredients. Despite the appeal, supplement trade groups are leery of opening up DSHEA to amendment.

In Brief

J&J loses $10M Stevens-Johnson suit

Matrixx Bought By Private Equity Firm H.I.G., Settles Personal Injury Lawsuits

Matrixx Initiatives announced Dec. 14 private equity firm H.I.G. Capital will acquire the Scottsdale, Ariz.-based maker of Zicam cough/cold products for approximately $75.2 million.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

RS125007

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel